Citations

Clear

363 citation(s) found for "Gray, RJ".

Profiling drug sensitivity in CLL B cells after BTK inhibitor progression using a novel drug panel
Han, Weiguo, Guzman, Emmanuel Contreras, Bhattacharya, Aisharya, Sinha, Sutapa, Wang, Zhiquan, Rabe, Kari, Anthony, Stephen, Gray, Nathanael, Crabtree, Gerald, Braggio, Esteban, Kenderian, Saad, Parikh, Sameer, Kay, Neil, Gray, Nathanael S. , Gray, Nathanael S , Han, Weiguo, Guzman, Emmanuel Contreras, Bhattacharya, Aisharya, Sinha, Sutapa, Wang, Zhiquan, Rabe, Kari, Anthony, Stephen, Gray, Nathanael, Crabtree, Gerald, Braggio, Esteban, Kenderian, Saad, Parikh, Sameer, Kay, Neil

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 7407-7407

10.1182/blood-2025-7407 Get It

Abstract Introduction: Although current clinical treatment approaches targeting Bruton Tyrosine Kinase (BTK) and BCL2, either as monotherapy or in combination are highly effective in chronic lymphocytic leukemia (CLL), CLL remains incurable. Identifying novel drugs that are potent and effective in the relapsed/refractory (RR) setting remains an unmet need. Methods: Utilizing the CellTiter-Glo 2.0 Cell Viability Assay, we have developed a preclinical drug screening platform which allows conducting drug sensitivity profiling of primary peripheral blood mononuclear cells (PBMCs) collected from CLL patients to a panel of drugs, in the presence and/or absence of bone marrow stromal cells (BMSCs). This unique system mimics the in vivo stromal microenvironment in CLL and enables testing of multiple drug responses in primary patient samples, particularly when leukemic cell numbers are low. In this study, we employed this high throughput drug screening platform to profile drug sensitivity in CLL B cells after disease progression on a BTK inhibitor (BTKi) to a panel of 12 drugs, including inhibitors of BCL2 (venetoclax and LP-118 [Newave]), AXL (TP-0903), histone deacetylase (panobinostat and belinostat), p53 (eprenetapopt and idasanutlin), proteasome (carfizomib) and Type III Receptor Tyrosine Kinase (crenolanib), next generation BTKi (LP-168 [Newave]), as well as a novel anti-cancer drug transcriptional chemical inducer of proximity (TCIP1) and the natural green tea extract (GTE) product Sunphenon 90D (Taiyo International). After 24-hour drug exposure, leukemic cell viability was measured, killing curves and IC50 levels generated and calculated by nonlinear curve regression in GraphPad Prism. Results: Using the Mayo Clinic CLL Database and the Mayo Clinic CLL Tissue Bank, we identified 47 patients with RR CLL, all of whom experienced disease progressionon a BTKi (35 ibrutinib +/- CD20 antibody, 10 acalabrutinib +/- CD20 antibody, 2 other). Median age at BTKi initiation was 64 years (range, 41-82), and 36 (77%) were male. IGHV status was unmutated in 44 (94%) patients, FISH at diagnosis showed del17p in 11 (27%), del11q in 6 (15%), +12 in 5 (12%), del13q in 12 (30%), and not detected in 6 (15%) patients. TP53 mutation was seen in 13 (32%) patients at the start of BTKi therapy. Median number of lines of CLL therapy prior to start of BTKi was 2 (range, 0–8); 13 patients received BTKi as their first-line therapy. Our drug screening results showed definite responses to all tested drugs based on dose range generated killing curves and IC50 levels for 30 RR CLL patient samples, though results varied. Among 12 drugs tested, LP-118 (0.1nM), venetoclax (2.6nM), carfizomib (2.2nM), TP-0903 (116.2nM), crenolanib (1769nM), and TCIP1 (1805nM) demonstrated the highest killing effects, while the remaining generated killing but at higher doses: belinostat (6800nM), eprenetapopt (4500nM), idasanutlin (4900nM), LP-168 (7500nM) and GTE (55.6uM). We also observed that RR CLL cohort exhibited significantly increased drug resistance to most of the tested drugs in the presence of BMSCs with corresponding increases in IC50s (with vs. without BMSCs, fold-change respectively): LP-118 3.92-fold, venetoclax 1.98-fold, carfilzomib 2.58-fold, TP-0903 1.65-fold, panobinostat 204.23-fold, TCIP1 1.91-fold, crenolanib 1.31-fold, idasanutlin 1.69-fold, belinostat 6.14-fold, LP-168 1.29-fold, eprenetapopt 3.44-fold and GTE 1.08-fold (11 out of 12 with p-values <0.05 except for GTE which was not significant, Mann-Whitney U test). We found that even for three drugs with the strongest killing effect based on IC50 levels (LP-118, venetoclax, carfilzomib), their killing effects were significantly reduced in the presence of BMSC (p=0.0002, 0.0002, and <0.0001, respectively). Conclusions: Our results highlight the spectrum of currently available drugs that show promise for therapeutic use in patients with RR CLL who experience disease progression on BTKi. The killing impact was still seen, albeit diminished, even in the presence of BMSC. Our ongoing work will be to associate the drug profiles with each patient's clinical history, as well as to the comprehensive genetic and epigenetic features of the CLL B cell clone.
sEEG ‐guided responsive neurostimulation to treat neocortical epilepsy: A multicenter retrospective study of the efficacy and safety of depth electrode‐mediated neuromodulation
Sadeghzadeh, Sina , Purger, David , Bhanot, Priya , Johnson, Noriah , Schonfeld, Ethan , Abikenari, Matthew , Jain, Bhav , Aronson, Joshua P. , Drees, Cornelia , Fisher, Tiffany , Gray, Tyler E. , Ojemann, Steven , Sather, Michael D., Skidmore, Christopher , Yoo, Ji Yeoun , Graber, Kevin , Halpern, Casey H. , Buch, Vivek , Parker, Jonathon J. , Drees, Cornelia , Gray, Tyler E , Hines, Kevin , Karakis, Ioannis , Quraishi, Imran H , Raslan, Ahmed M , Wu, Chengyuan , Yoo, Ji Yeoun , Buch, Vivek , Skidmore, Christopher , Barbosa, Daniel A. N. , Huang, Yuhao , Park, Jay J. , Gerrard, Jason L. , Ghatan, Saadi , Jobst, Barbara C. , Karakis, Ioannis , Willie, Jon T , Wu, Chengyuan

Mayo Clinic

Epilepsia Open | November 18, 2025 | Volume: 11 | Issue: 1 | Pages: 146-161

10.1002/epi4.70180 | PMID 41251192 Get It

Abstract Objectives Pivotal trials have established the effectiveness of the Responsive Neurostimulation System (RNS® System) in treating focal epilepsy. In clinical trials, depth leads were primarily used to treat mesial temporal seizure onsets while cortical strip leads were used to treat neocortical seizure onsets. Here, we systematically analyze the safety and efficacy of stereoelectroencephalography (sEEG)‐guided depth leads to provide responsive stimulation to neocortical gray matter. Methods Patients were stratified as strong responders (>median cohort seizure reduction %), weak responders (>0% and ≤median cohort seizure reduction %), and anti‐responders (≤0%) based on percent seizure reduction at 1 year post‐implant (1‐Y). Pre‐operative T1‐weighted magnetic resonance imaging and post‐operative computed tomography images were merged, and the Euclidean distance between the sEEG epileptic focus (sEEG‐EF) and the nearest RNS System depth lead contacts was calculated. Results A total of 87 depth leads were implanted in 55 patients across neocortical brain regions. The median reduction in clinical seizures improved from 66.7% at 1‐Y to 77.5% at long‐term follow‐up (LTFU: 2.35 ± 0.95 years), with 10 patients (18.2%) achieving complete seizure freedom. Seven patients (12.7%) experienced six serious adverse events. At 1‐Y, shorter Euclidean distance between the sEEG‐EF and RNS System depth leads predicted improved seizure outcome in strong responders ( β = −0.84, p = 0.008) but not in weak responders ( β = 0.21, p = 0.9) or anti‐responders ( β = −20.34, p = 0.11). At LTFU, there was no significant relationship between Euclidean distance and seizure reduction in strong responders ( β = 0.77, p = 0.18), weak responders ( β = 2.05, p = 0.54), or anti‐responders ( β = 0.24, p = 0.99). Exploratory analyses at 1‐Y showed nominal associations between older age ( ρ = 0.32), longer epilepsy duration ( ρ = 0.27), and non‐mesial temporal sEEG‐EFs and greater seizure reduction; however, none survived Bonferroni correction (adjusted α = 0.0027; all post‐correction p > 0.0027), and no associations were observed at LTFU. Significance In this series, neocortical depth leads for RNS therapy had favorable safety and efficacy and proximity to the sEEG‐EF drove initial outcomes for strong responders to RNS therapy. Plain Language Summary In this multi‐center study, patients with difficult‐to‐treat seizures received brain‐responsive stimulation using a device called responsive neurostimulation (RNS), which delivers small electrical pulses to reduce seizures. We focused on patients treated with electrodes placed in the brain's outer regions (the neocortex) and guided by a mapping procedure called sEEG. On average, patients had their seizures cut by two‐thirds after one year and by more than three‐quarters with longer follow‐up, with about one in five becoming seizure‐free. The treatment was safe, and closer electrode placement to the seizure source helped explain early—but not long‐term—improvements.
Diffusion Alterations at the Gray Matter/White Matter Boundary in Traumatic Encephalopathy Syndrome
Wiegand, Tim L. T. , Pankatz, Lara, Arciniega, Hector , Jung, Leonard , Tuz‐Zahra, Fatima , Lubeck, Haley, Rojczyk, Philine , Schuhmacher, Luisa Sophie, Buring, J. E., Pasternak, Ofer , Cetin-Karayumak, Suheyla, McKee, Ann C. , Balcer, Laura J. , Bernick, Charles , Coleman, Michael J. , Colasurdo, Elizabeth A. , Lin, Alexander , Peskind, Elaine R. , Blennow, Kaj, Zetterberg, Henrik, Alosco, Michael L. , Cummings, Jeffrey L., Reiman, Eric M. , Stern, Robert , Shenton, Martha E., Bouix, Sylvain , Katz, Douglas I. , Tripodis, Yorghos , Karayumak, Suheyla Cetin , Rathi, Yogesh , Adler, Charles H. , Ashton, Nicholas J. , Blennow, Kaj , Zetterberg, Henrik , Stern, Robert A., Koerte, Inga K

Mayo Clinic

Journal of Neurotrauma | November 12, 2025 | Volume: 43 | Issue: 3-4 | Pages: 224-235

10.1177/08977151251393966 | PMID 41218808 Get It

Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with exposure to repetitive head impacts (RHI). In CTE, hyperphosphorylated tau (p-tau) aggregates are found in neurons at the depth of cortical sulci close to the gray matter/white matter (GM/WM) boundary. To date, CTE can only be diagnosed postmortem by neuropathological examination. Traumatic encephalopathy syndrome (TES) is the clinical syndrome purported to be associated with CTE pathology. The aim of this study is to investigate microstructural properties at the GM/WM boundary in individuals with a history of exposure to RHI and clinical features of CTE (i.e., TES). Diffusion magnetic resonance imaging (dMRI), TES diagnoses, and cerebrospinal fluid (CSF) biomarkers were acquired from 165 male former American football players (age: 57.29 ± 8.23 years) from the DIAGNOSE CTE Research Project, a multicenter, observational cohort study. Fractional anisotropy (FA) was measured at the GM/WM boundary of the whole brain. In addition, a widely used method (tract-based spatial statistics [TBSS]) was applied to measure FA of central WM. We used analyses of covariance to test associations between FA and TES. Furthermore, we used linear regressions to test associations between FA and nine CSF biomarkers (i.e., p-tau-181, -217, -231, total tau, amyloid β [Aβ] 1–40 , Aβ 1–42 , glial fibrillary acidic protein [GFAP], neurofilament light [NfL], and soluble triggering receptor expressed on myeloid cells-2 [sTREM2]). We report an association between higher FA at the GM/WM boundary and higher levels of certainty for CTE pathology ( F (1, 147) = 5.781, 95% confidence interval (CI) = 0.0003–0.003, p = 0.035) as well as neurobehavioral dysregulation ( F (1, 148) = 7.559, 95% CI = 0.001–0.009, p = 0.020), and functional dependence/dementia ( F (1, 148) = 5.046, 95% CI = 0.0004–0.006, p = 0.039). In addition, we report an association between higher FA at the GM/WM boundary and higher CSF p-tau-181 (β = 0.272, 95% CI = 0.078–0.466, p = 0.029) and p-tau-217 (β = 0.295, 95% CI = 0.102–0.488, p = 0.027). FA of the central WM was not associated with TES diagnoses. Taken together, these findings suggest that dMRI at the GM/WM boundary could be used to investigate microstructural alterations suggestive of tau pathology-associated neurodegeneration in individuals with TES, the clinical presentation of CTE. Future studies are needed to validate this approach and to identify clinically useful cutoff values for dMRI metrics.
The contribution of lumbar puncture opening pressure in the diagnosis of spontaneous intracranial hypotension: A systematic literature review and meta‐analysis
Parikh, Simy , Deline, Constance R., McCreary, Morgan , Amoozegar, Farnaz , Amrhein, Timothy J. , Carroll, Ian , Cutsforth‐Gregory, Jeremy K. , Leithe, Linda Gray, Kranz, Peter G. , Louy, Charles, Maya, M. Marcel , Rau, Jill C. , Silberstein, Stephen D., Schievink, Wouter I., Parikh, Simy , Amrhein, Timothy J , Carroll, Ian , McCreary, M , Kranz, Peter G , Moghekar, Abhay , Schievink, Wouter I. , Friedman, Deborah I.

Mayo Clinic

Headache: The Journal of Head and Face Pain | October 15, 2025 | Volume: 66 | Issue: 2 | Pages: 517-530

10.1111/head.15060 | PMID 41090555 Get It

Abstract Objective The objective of this study was to summarize the available evidence regarding the clinical value and trend over time of lumbar cerebrospinal fluid (CSF) opening pressure utilization to diagnose spontaneous intracranial hypotension (SIH). Background CSF opening pressure obtained via lumbar puncture is one of the diagnostic criteria for SIH based on the International Criteria for Headache Disorders, 3rd Edition (ICHD‐3), but it has questionable utility as an initial investigation for diagnosing SIH. Methods The authors performed a systematic literature review and meta‐analysis. PubMed/MEDLINE, Scopus, and Cochrane Library were searched from inception to October 2022. Original studies and case series in English reporting three or more patients with suspected or known SIH and CSF pressure measurement were included. Meta‐analyses and meta‐regression were used to calculate pooled estimates and examine the impact of age, sex, and publication year on outcomes, including CSF pressure < 60 mm CSF, orthostatic headache, and positive findings on brain magnetic resonance imaging (MRI), spinal imaging, and radionuclide studies. Results For every 1‐year increase in the year of publication, the odds of reporting low CSF pressure decreased by 6.20% (adjusted odds ratio [aOR] = 0.94, aOR 95% confidence interval [CI] = [0.90, 0.97], p = 0.001), the odds of reporting a positive brain MRI increased by 4.67% (aOR = 1.05, aOR 95% CI = [1.01, 1.09], p = 0.026), and the odds of reporting orthostatic headache increased by 9.13% (aOR = 1.09, aOR 95% CI = [1.03, 1.15], p = 0.002). Each 1% increase in the percentage of patients with orthostatic headache was associated with a 3.13% increase in the odds of low CSF pressure (aOR = 1.03, aOR 95% CI = [1.01, 1.05], p = 0.003). Similarly, as the percentage of patients with low CSF pressure increased by 1%, there was a 2.53% increase in the odds of orthostatic headache (aOR = 1.03, aOR 95% CI = [1.01, 1.04], p = 0.005). It was estimated that 31.9% of patients with SIH had normal opening pressure (95% CI = [24.0%, 40.8%], prediction interval = [5.0%, 80.5%]). Every 1% increase in the percentage of patients with positive brain MRI was associated with a 5.25% increase in the odds of positive spinal imaging (aOR = 1.05, aOR 95% CI = [1.00, 1.11], p = 0.047). Age and positive radionuclide study did not significantly impact the outcomes measured. The corresponding I 2 for each outcome was reduced by controlling for study‐wide covariates believed to impact the prevalence of each outcome. Sensitivity analyses did not reveal discrepancies in results when studies requiring outcomes of interest were removed. Conclusion Our analysis found that recent studies indicate a reduced reliance on opening pressure for diagnosing SIH. Rather, results suggest an increasing reliance on contrast‐enhanced brain MRI, spine imaging, and clinical features for SIH diagnosis.
Mortality in the Sepsis-3 Era: A Systematic Review of Multicenter Randomized Controlled Trials
Karakuş, İbrahim Serhat , Gmehlin, G. Cameron, Halpern, Gabriele Alves, Ghafouri, Kimia , Abramovich, Sergej, Raghu, Roshini , Pastrak, Mila, Dana, Gerberi J., Odeyemi, Yewande , Gmehlin, Cameron G. , Nemet, Marko , Gmehlin, Cameron Gray, Alves Halpern, Gabriele, Nikravangolsefid, Nasrin , Gerberi, Dana J., Herasevich, Svetlana , Abramovich, Sergej, Lal, Amos , Gajic, Ognjen

Mayo Clinic

Shock | September 25, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/shk.0000000000002687 | PMID 40997273 Get It

This systematic review examined multicenter randomized controlled trials (RCTs) conducted during the Sepsis-3 era that evaluated pharmaceutical and mechanistic interventions in adult patients with sepsis or septic shock, with a focus on identifying interventions that demonstrated mortality benefit. A comprehensive search was performed across Ovid MEDLINE, Embase, Cochrane Central, ClinicalTrials.gov, WHO ICTRP, and Web of Science for trials published since 2016. Studies were included if they enrolled adult patients with sepsis or septic shock using Sepsis-3 criteria and reported mortality as either a primary or secondary outcome. Data were extracted by two independent reviewers and included trial design characteristics, funding source, randomization methods, and reported outcomes. Among the 31 eligible multicenter RCTs enrolling over 7,000 patients across 550 centers, only four trials showed a mortality benefit. These included three studies from China—two evaluating herbal anti-inflammatory compounds and one evaluating aminophylline—and one European study assessing corticosteroid therapy in vasopressor-dependent septic shock. The remaining 27 trials reported no mortality benefit, and substantial heterogeneity was observed in patient populations, sepsis definitions, and outcome reporting. Median mortality in control arms was 31.6% (IQR 24.1–45.5), and 35.4% (IQR 25.7–49.6) in intervention arms. These findings suggest that despite extensive efforts, most interventions have not reduced mortality in multicenter sepsis trials. Future research should focus on optimizing trial design, refining patient selection, and incorporating patient-centered outcomes beyond mortality.
Safety and efficacy of the ShangRing for early infant male circumcision in the routine clinical setting
Calderon, Lina Posada , Ho, Kaylee, Barone, Mark A. , Awori, Quentin , Ouma, Daniel, Oketch, Jairus, Christensen, Alice, Hellar, Augustino , Makokha, Maende, Isangu, Alphonce, Salim, Robert, Lija, Jackson, Gray, Ronald H. , Kiboneka, Stephen, Anok, Aggrey , Kigozi, Godfrey , Nakabuye, Regina, Ddamulira, Charles, Odiya, Silas, Goldstein, Marc , Li, Philip S. , Lee, Richard K. , Posada Calderon, Lina , Basourakos, Spyridon P. , Hellar, Augustino , Ballman, Karla V.

Mayo Clinic

BMJ Global Health | September 25, 2025 | Volume: 10 | Issue: 9 | Pages: e017903

10.1136/bmjgh-2024-017903 | PMID 40998526 Get It

Introduction Male circumcision (MC) has been shown to decrease transmission of HIV and is a critical strategy to decrease its incidence in countries with high rates of heterosexually transmitted HIV. Early infant MC (EIMC), with single-use MC devices, could increase rates of MC in Sub-Saharan Africa. Our objective was to determine the safety, efficacy and satisfaction of ShangRing EIMC in resource-constrained environments. Methods Healthy male infants aged 1–60 days underwent ShangRing EIMC performed by non-physician clinicians in 14 sites in Kenya, Tanzania and Uganda. The primary outcomes were the safety and efficacy of ShangRing EIMC. Secondary outcomes were pain related to the procedure, wound healing and parental satisfaction. Male infants were assessed at discharge and on postoperative days 7 and 28 for wound healing and complications. This trial is registered with Clinical.Trials.gov, NCT03338699 , and is complete. Results From the 1697 participants enrolled from February to November 2020, 1691 (99.6%) underwent ShangRing EIMC. Median duration of the procedure was 10 min (IQR 6–13). The mean Neonatal Infant Pain Scale 20 min postprocedure was 0.3 (SD 0.8), indicating no pain. At the time of discharge, 1679 (99.0%) participants had a normal-appearing wound and 1574 (93.1%) demonstrated complete wound healing at 28 days. A total of 17 (1.0%) AEs were reported, most related to bleeding. A total of 1635 (99.1%) of parents were satisfied with the appearance of the circumcised penis at 28 days. Conclusion ShangRing EIMC is a simple and successful MC method that non-physician clinicians can perform safely, with low AE rate, satisfactory wound healing and high satisfaction rate among parents. This indicates that the ShangRing EIMC can be considered a long-term strategic approach to accelerate the scale-up of MC in Sub-Saharan Africa. Trial registration number NCT03338699 .
Molecular Breast Imaging and Digital Breast Tomosynthesis for Dense Breast Screening: The Density MATTERS Trial
Hruska, Carrie B. , Hunt, Katie N. , Larson, Nicholas B. , Miller, Patricia A. , Ellis, Richard L. , Shermis, Robin B. , Rauch, Gaiane M. , Conners, Amy Lynn , Spilde, Jeannette Gasal, Semaan, D., Siegal, Emily C. , Zingula, Shannon N. , Mandava, Sabala, Martin, Tamara S., Ahmed, Riffat K., Whaley, Dana H. , Gray, Lacey R., Mehta, Ramila A. , Roll, Rebecca J, O’Connor, Michael K. , Rhodes, Deborah J. , Gasal Spilde, Jeannette, Mandava, Sabala R , Adrada, Beatriz E , Gray, Lacey R , Mehta, Ramila A , Roll, Rebecca J , Redfern, Roberta E , O'Connor, Michael K , Rhodes, Deborah J , Hruska, Carrie B , Larson, Nicholas B , Rauch, Gaiane M , Ahmed, Riffat K., Adrada, Beatriz E. , Redfern, Roberta E.

Mayo Clinic

Radiology | September 23, 2025 | Volume: 316 | Issue: 3 | Pages: No page available

10.1148/radiol.243953 | PMID 40985829 Get It

In women with dense breasts, adding molecular breast imaging to digital breast tomosynthesis (DBT) increased both overall and invasive cancer detection rates, while modestly raising the recall rate compared with DBT alone.
Visible Light Induced DLP‐Printed Oxygen‐Releasing TPMS Scaffolds Mitigate Early Hypoxia in Bone Defects
Timoshenko, Anastasia B., Ghasemkhani, Ali, Kim, Chanul , Cordova, Domenic J., Potes, Maria Astudillo , Aceves, Valeria , Mitra, Indranath , Bird, Justin E. , Elder, Benjamin D. , Tilton, Maryam , Tilton, Maryam , Gray, Ryan S. , Seidlits, Stephanie K.

Mayo Clinic

Advanced Healthcare Materials | September 23, 2025 | Volume: 15 | Issue: 3 | Pages: No page available

10.1002/adhm.202502735 | PMID 40985752 Get It

Abstract Oxygen deprivation within large or poorly vascularized bone defects remains a key barrier to successful regeneration, especially during the early postimplantation period before vascular ingrowth. Here, the development of COSnPPOD (CaO 2 –Silica NP Platform for Osteogenic Development) is reported, a visible light digital light processing‐printed hydrogel scaffold that integrates oxygen‐releasing nanoparticles (NPs) within a Primitive‐type triply periodic minimal surface architecture. The scaffold combines a gelatin methacrylate‐poly(ethylene glycol) diacrylate matrix with calcium peroxide (CaO 2 )‐loaded hollow silica NPs, enabling localized, short‐term oxygen release while preserving structural fidelity. COSnPPOD scaffolds demonstrate favorable degradation kinetics, tunable stiffness, and increased protein adsorption in vitro. In a preosteoblast model, COSnPPOD maintains cell viability and supports osteogenic gene expression without cytotoxic effects. While overall gene expression is comparable to controls, a 16‐fold increased expression of phosphoprotein 1 (Spp1) suggests scaffold‐driven activation of matrix remodeling pathways. In vivo, COSnPPOD scaffolds enhance bone regeneration in a murine calvarial defect model, with significantly greater bone formation and collagen deposition than untreated defects and hydrogel controls. Additionally, vascular endothelial growth factor immunostaining is increased within the defect, consistent with a proangiogenic response, and no systemic toxicity is observed. These findings establish COSnPPOD as a promising scaffold system that combines sustained oxygenation with biomimetic geometry to support localized bone regeneration.
Quality measures for care of patients with restless legs syndrome: 2025 update after measure maintenance
Lloyd, Robin M. , Crawford, T’Auna, Donald, Ryan, Gray, Diedra D., Junna, Mithri R. , Lewin, Daniel , Revana, Amee , Schutte-Rodin, Sharon, Healy, William J.

Mayo Clinic

Journal of Clinical Sleep Medicine | September 17, 2025 | Volume: 21 | Issue: 12 | Pages: 2205-2211

10.5664/jcsm.11894 | PMID 40958636 Get It

Challenges in the return of molecular tumor profiling results
Lenz, Heinz-Josef, Craig, David W. , Johnson, Kevin C. , Verhaak, Roel G.W. , Bhattacharyya, Oindrila , Davis, Bethany , Wesley, C. John, Byron, Sara A. , Willman, Cheryl L. , Kelley, Lindsey , Claus, Elizabeth B. , Trent, Jeffrey M. , Culver, Julie O. , Church, Alanna J. , Lenz, Heinz-Josef , Verhaak, Roel Gw , Willman, Cheryl , Trent, Jeffrey M , Gray, Stacy W , Church, Alanna J , Wesley, Cherie, Kelley, Lindsey , Claus, Elizabeth B , Gray, Stacy W.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 5, 2025 | Volume: 118 | Issue: 5 | Pages: 776-782

10.1093/jnci/djaf251 | PMID 40929086 Get It

Abstract Next-generation sequencing has transformed cancer care by providing essential insights for diagnosis, prognosis, and treatment. However, variability in testing timing, reporting practices, and interpretation challenges limits its clinical impact. This article highlights key opportunities to optimize somatic reporting, emphasizing the importance of timely testing throughout the cancer care continuum to maximize the diagnostic and therapeutic relevance of findings. Technical factors such as test design, sequencing depth, and the use of liquid biopsy substantially influence result accuracy and interpretation, underscoring the need for careful integration with clinical history. Standardized reporting practices that clearly delineate diagnostic, prognostic, and therapeutic findings can enhance the clinical utility of next-generation sequencing results. Streamlined formats and curated clinical trial data further support actionable decision making. Additionally, direct patient engagement and education are essential for empowering patients to navigate genomic testing and make informed decisions about their care. By leveraging multidisciplinary tumor boards, decision-support tools, and emerging artificial intelligence technologies, clinicians can better navigate the complexities of somatic reports. Standardization and clarity in reporting are critical to advancing precision oncology, empowering providers and patients to make informed treatment decisions and improve outcomes.